MedPath

Novavax

πŸ‡ΊπŸ‡ΈUnited States
Ownership
-
Employees
1.5K
Market Cap
$1.7B
Website
Introduction

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Clinical Trials
Related News

Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly Adults

Phase 2
Completed
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
Biological: Saline Placebo
Biological: RSV-F Vaccine
First Posted Date
2014-10-17
Last Posted Date
2022-05-27
Lead Sponsor
Novavax
Target Recruit Count
1599
Registration Number
NCT02266628
Locations
πŸ‡ΊπŸ‡Έ

Lisa Jackson, Seattle, Washington, United States

πŸ‡ΊπŸ‡Έ

Research Across America, Dallas, Texas, United States

πŸ‡ΊπŸ‡Έ

Nothern California Clinical Research, Redding, California, United States

and more 7 locations

RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.

Phase 2
Completed
Conditions
Respiratory Syncytial Virus Infections
Interventions
Drug: Saline Placebo (0.5mL injection)
Drug: RSV F vaccine (0.5mL injection)
First Posted Date
2014-09-25
Last Posted Date
2022-05-27
Lead Sponsor
Novavax
Target Recruit Count
50
Registration Number
NCT02247726
Locations
πŸ‡ΊπŸ‡Έ

Meridian Clinical Research, Norfolk, Nebraska, United States

πŸ‡ΊπŸ‡Έ

Baylor College of Medicine, Houston, Texas, United States

πŸ‡ΊπŸ‡Έ

Advanced Specialty Research, Nampa, Idaho, United States

and more 4 locations

A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1β„’ Adjuvant

Phase 1
Completed
Conditions
Influenza (Pandemic)
Interventions
Biological: Placebo
Biological: Monovalent Avian Influenza VLP (H7N9)
Biological: Matrix-M1β„’ adjuvant
First Posted Date
2014-03-05
Last Posted Date
2016-09-23
Lead Sponsor
Novavax
Target Recruit Count
610
Registration Number
NCT02078674
Locations
πŸ‡ΊπŸ‡Έ

Diablo Clinical Research, Walnut Creek, California, United States

πŸ‡ΊπŸ‡Έ

Miami Research Associates, Miami, Florida, United States

πŸ‡ΊπŸ‡Έ

Coastal Carolina Research, Mt. Pleasant, South Carolina, United States

and more 2 locations

RSV F Dose-Ranging Study in Women

Phase 2
Completed
Conditions
Respiratory Syncytial Virus Infections
Interventions
Biological: Low dose RSV F Antigen
Biological: High dose RSV F Antigen
Biological: Dose 3 of Aluminum Adjuvant
Biological: Dose 4 of Aluminum Adjuvant
Biological: Dose 1 of Aluminum Adjuvant
Biological: Dose 2 of Aluminum Adjuvant
Biological: Placebo
First Posted Date
2013-10-11
Last Posted Date
2016-05-26
Lead Sponsor
Novavax
Target Recruit Count
720
Registration Number
NCT01960686
Locations
πŸ‡ΊπŸ‡Έ

Wake Research Associates, Raleigh, North Carolina, United States

πŸ‡ΊπŸ‡Έ

Diablo Clinical Research, Walnut Creek, California, United States

πŸ‡ΊπŸ‡Έ

Clincal Research of Atlanta, Stockbridge, Georgia, United States

and more 7 locations

A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1

Phase 1
Completed
Conditions
Avian Influenza
Interventions
Biological: Monovalent Avian Influenza VLP (H7N9)
Biological: Placebo
Biological: Adjuvant 1
First Posted Date
2013-07-12
Last Posted Date
2014-10-13
Lead Sponsor
Novavax
Target Recruit Count
280
Registration Number
NCT01897701
Locations
πŸ‡¦πŸ‡Ί

Linear Clinical Research, Nedlands, Western Australia, Australia

πŸ‡¦πŸ‡Ί

CMAX, Adelaide, South Australia, Australia

πŸ‡¦πŸ‡Ί

Q-Pharm Pty Limited, Herston, Queensland, Australia

RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly

Phase 1
Completed
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
Biological: Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
Biological: Placebo (Day 0 & Day 28); Seasonal TIV (Day 0)
Biological: High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
Biological: Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28)
Biological: High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
First Posted Date
2012-10-17
Last Posted Date
2014-03-05
Lead Sponsor
Novavax
Target Recruit Count
220
Registration Number
NCT01709019
Locations
πŸ‡ΊπŸ‡Έ

Jean Brown Research, Salt Lake City, Utah, United States

πŸ‡ΊπŸ‡Έ

Accelovance, Melbourne, Florida, United States

πŸ‡ΊπŸ‡Έ

Research Across America, Dallas, Texas, United States

and more 1 locations

RSV-F Vaccine Dose Ranging Study in Young Women

Phase 2
Completed
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
Biological: Low dose RSV-F Vaccine without Adjuvant
Biological: High dose RSV-F Vaccine with Adjuvant
Biological: High dose RSV-F Vaccine without Adjuvant
Biological: Low dose RSV-F Vaccine with Adjuvant
Biological: Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing]
Biological: Placebo
First Posted Date
2012-10-11
Last Posted Date
2014-03-07
Lead Sponsor
Novavax
Target Recruit Count
330
Registration Number
NCT01704365
Locations
πŸ‡ΊπŸ‡Έ

Anaheim Clinical Trials, Anaheim, California, United States

πŸ‡ΊπŸ‡Έ

Accelovance Rockville, Rockville, Maryland, United States

πŸ‡ΊπŸ‡Έ

Clinical Trials of Texas, San Antonio, Texas, United States

and more 1 locations

A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2

Phase 1
Completed
Conditions
Influenza (Pandemic)
Interventions
Biological: Monovalent Avian Influenza VLP (H5N1); Adjuvant
Biological: Monovalent Avian Influenza VLP (H5N1)
Biological: Saline Placebo
First Posted Date
2012-05-11
Last Posted Date
2014-02-06
Lead Sponsor
Novavax
Target Recruit Count
333
Registration Number
NCT01596725
Locations
πŸ‡ΊπŸ‡Έ

Anaheim Clinical Trials, Anaheim, California, United States

πŸ‡ΊπŸ‡Έ

Miami Research Associates, Miami, Florida, United States

πŸ‡ΊπŸ‡Έ

Broward Research Group, Pembroke Pines, Florida, United States

and more 2 locations

A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1

Phase 1
Completed
Conditions
Influenza (Pandemic)
Interventions
Biological: Monovalent Avian Influenza VLP (H5N1); Adjuvant
Biological: Saline placebo
Biological: Monovalent Avian Influenza VLP (H5N1)
First Posted Date
2012-05-09
Last Posted Date
2014-02-06
Lead Sponsor
Novavax
Target Recruit Count
333
Registration Number
NCT01594320
Locations
πŸ‡ΊπŸ‡Έ

Johnson County Clin-Trials, Lenexa, Kansas, United States

πŸ‡ΊπŸ‡Έ

Miami Research Associates, Miami, Florida, United States

πŸ‡ΊπŸ‡Έ

Broward Research Group, Pembroke Pines, Florida, United States

and more 2 locations

A Study to Evaluate the Immune Response and Safety of a Seasonal Virus-Like Particle Influenza Vaccine in Healthy Young Adults

Phase 2
Completed
Conditions
Influenza
Interventions
Biological: Novavax Quadrivalent vaccine
Biological: Novavax Trivalent vaccine
Biological: cTIV
First Posted Date
2012-03-23
Last Posted Date
2013-07-18
Lead Sponsor
Novavax
Target Recruit Count
500
Registration Number
NCT01561768
Locations
πŸ‡¦πŸ‡Ί

CMAX, Adelaide, Australia

πŸ‡¦πŸ‡Ί

Emeritus Research, Melbourne, Australia

πŸ‡¦πŸ‡Ί

Linear Clinical Research, Perth, Australia

and more 1 locations
Β© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy